Valeur202020212022202320242025TTMFlux de trésorerie liés aux activités d'investissement-100.12 M-294.14 M-461.34 M71.84 M185.01 M-121.44 M28.92 MFlux de trésorerie liés aux activités de financement322.32 M756.14 M111.59 M276.45 M7.74 M478.05 M101.28 MFlux de trésorerie disponible-95.74 M-66.27 M22.53 M-149.19 M-347.25 M-360.05 M-383.84 M
Beam Therapeutics Inc. - Common Stock
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.